Sprifermin moves FORWARD with sustained effects in osteoarthritis

There was a statistically significant treatment effect and dose response effect seen in TFJ cartilage thickness.

“Although cartilage thickness declined in all treatment groups between years 2 and 3, the difference in cartilage thickness observed in year 2 with sprifermin at the highest dose [100 mcg every 6 months] versus placebo persisted through year 3,” Dr. Hochberg said at the congress, which was sponsored by the Osteoarthritis Research Society International.

^{Sara Freeman/MDedge News}

Dr. Marc Hochberg

As for secondary endpoints of thickness in the medial and lateral tibiofemoral cartilage, “there are significant differences between the higher-dose sprifermin group and the placebo group,” he said.

“Based on imaging, sprifermin appears to be effective at modifying structural changes in articular cartilage in a dose-dependent manner in patients with knee osteoarthritis, with an acceptable safety profile.”